Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: A review of clinical trials

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Molino, Ivana ^a   Colucci, Luisa ^a   Fasanaro, Angiola M ^b   Traini, Enea ^a   Amenta, Francesco ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b Azienda Ospedaliera di Rilievo Nazionale v Monaldi   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; DONEPEZIL PLUS MEMANTINE; MEMANTINE; PLACEBO; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES FOR DAILY LIVING; CAREGIVER BURDEN; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE PLUS; COGNITION; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT STAGING; GLOBAL DETERIORATION SCALE; HUMAN; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHIATRIC INVENTORY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDENTIAL CARE; REVIEW; SEVERE IMPAIRMENT BATTERY; SYSTEMATIC REVIEW; AGED; FEMALE; MALE; META ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; INDANS; MALE; MEMANTINE; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84888632992     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/925702     Document Type: Review

References (45)

1. Alzheimer's Disease Internationl, World Alzheimer Report 2010: the global economic impact of dementia. http://www.alz.org/documents/national/World- Alzheimer-Report-2010.pdf
2. EMEA Committee for Medicinal Products for Human Use, Plenary meeting monthly report. October 2005, European Medicines Agency, http://www.emea.europa. eu/pdfs/human/press/pr/36234805en.pdf
3. Grossberg G. T., Pejović V., Miller M. L., Graham S. M., Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2009 27 2 164 172 2-s2.0-59249084336 10.1159/000200013
4. National Institute for Clinical Excellence (NICE), Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE Technology Appraisal Guidance 2011 217 London, UK National Institute for Clinical Excellence. (Review of NICE Technology Appraisal Guidance 111)
5. Institute for Quality and Efficiency in Health Care (IQWiG), Federal Joint Committee, Responder analyses on memantine in Alzheimer's disease. Executive Summary of Rapid Report 2011 A 10-06 Institute for Quality and Efficiency in Healthcare (IQWiG)
6. Winblad B., Jones R. W., Wirth Y., Stöffler A., Möbius H. J., Memantine in moderate-to-severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders 2007 24 1 20 27 (Pubitemid 46985287)
7. Thomas S. J., Grossberg G. T., Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clinical Interventions in Aging 2009 4 367 377 2-s2.0-77950350271
8. Doody R. S., Dunn J. K., Clark C. M., Farlow M., Foster N. L., Liao T., Gonzales N., Lai E., Massman P., Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2001 12 4 295 300 2-s2.0-0035001864 10.1159/000051272 (Pubitemid 32429729)
9. Clegg A., Bryant J., Nicholson T., McIntyre L., De Broe S., Gerard K., Waugh N., Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technology Assessment 2001 5 1 1 137 2-s2.0-18544403400
10. Hansen R. A., Gartlehner G., Webb A. P., Morgan L. C., Moore C. G., Jonas D. E., Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clinical Interventions in Aging 2008 3 2 211 225 2-s2.0-47849119964 (Pubitemid 352037861)
11. Christensen D. D., Higher-dose (23 mg/dayay) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease. Postgraduate Medicine 2012 124 6 110 116
12. Cummings J. L., Geldmacher D., Farlow M., Sabbagh M., Christensen D., Betz P., High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neuroscience & Therapeutics 2013 19 5 294 301
13. Ferris S., Cummings J., Christensen D., Doody R., Farlow M., Sabbagh M., Liu L., Mackell J., Fain R., Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate-to-severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimer's Research & Therapy 2013 5 1, article 12
14. Atri A., Molinuevo J. L., Lemming O., Wirth Y., Pulte I., Wilkinson D., Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimer's Research & Therapy 2013 5 1, article 6
15. Gauthier S., Molinuevo J. L., Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimer's & Dementia 2013 9 3 326 331
16. Wells G., Shea B., O'Connell D., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Metaanalysis 2011 Ottawa, Canada Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp
17. Fox C., Crugel M., Maidment I., Auestad B. H., Coulton S., Treloar A., Ballard C., Boustani M., Katona C., Livingston G., Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE 2012 7 5 2-s2.0-84860509122 10.1371/journal.pone.0035185 e35185
18. Förstl H., Stamouli S. S., Janetzky W., Galanopoulos A., Karageorgiou C., Tzanakaki M., Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dementia and Geriatric Cognitive Disorders 2011 32 4 267 272 2-s2.0-84855582695 10.1159/000334991
19. Herrmann N., Cappell J., Eryavec G. M., Lancôtt K. L., Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. CNS Drugs 2011 25 5 425 433 2-s2.0-79953869334 10.2165/11588160- 000000000-00000
20. Schulz J. B., Rainer M., Klünemann H., Kurz A., Wolf S., Sternberg K., Tennigkeit F., Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. Journal of Alzheimer's Disease 2011 25 3 463 475 2-s2.0-79959682427 10.3233/JAD-2011-101929
21. Rainer M., Wuschitz A., Jagsch C., Erb C., Chirikdjian J.-J., Mucke H. A. M., Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. Journal of Neural Transmission 2011 118 8 1255 1259 2-s2.0-80051601025 10.1007/s00702-011-0623-8
22. Wilcock G. K., Ballard C. G., Cooper J. A., Loft H., Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry 2008 69 3 341 348 2-s2.0-42249111378 (Pubitemid 351549385)
23. Carrasco M. M., Agüera L., Gil P., Moríñigo A., Leon T., Safety and effectiveness of donepezil on behavioral symptoms in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders 2011 25 4 333 340 2-s2.0-81855166615 10.1097/WAD.0b013e318212ab7a
24. Farlow M. R., Salloway S., Tariot P. N., Yardley J., Moline M. L., Wang Q., Brand-Schieber E., Zou H., Hsu T., Satlin A., Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clinical Therapeutics 2010 32 7 1234 1251 2-s2.0-77955253242 10.1016/j.clinthera.2010.06. 019
25. Farlow M., Veloso F., Moline M., Yardley J., Brand-Schieber E., Bibbiani F., Zou H., Hsu T., Satlin A., Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology 2011 11, article 57 2-s2.0-80052615524 10.1186/1471-2377-11-57
26. Schwam E., Xu Y., Cognition and function in Alzheimer's disease: Identifying the transitions from moderate to severe disease. Dementia and Geriatric Cognitive Disorders 2010 29 4 309 316 2-s2.0-77950828023 10.1159/000269837
27. Homma A., Imai Y., Tago H., Asada T., Shigeta M., Iwamoto T., Takita M., Arimoto I., Koma H., Ohbayashi T., Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dementia and Geriatric Cognitive Disorders 2008 25 5 399 407 2-s2.0-43049134839 10.1159/000122961 (Pubitemid 351630073)
28. Black S. E., Doody R., Li H., McRae T., Jambor K. M., Xu Y., Sun Y., Perdomo C. A., Richardson S., Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007 69 5 459 469 2-s2.0-34548081204 10.1212/01.wnl.0000266627.96040.5a (Pubitemid 47450281)
29. Howard R., McShane R., Lindesay J., Ritchie C., Baldwin A., Barber R., Burns A., Dening T., Findlay D., Holmes C., Hughes A., Jacoby R., Jones R., Jones R., McKeith I., Macharouthu A., O'Brien J., Passmore P., Sheehan B., Juszczak E., Katona C., Hills R., Knapp M., Ballard C., Brown R., Banerjee S., Onions C., Griffin M., Adams J., Gray R., Johnson T., Bentham P., Phillips P., Donepezil and memantine for moderate-to-severe Alzheimer's disease. The New England Journal of Medicine 2012 366 10 893 903 2-s2.0-84857843877 10.1056/NEJMoa1106668
30. Doody R. S., Geldmacher D. S., Farlow M. R., Sun Y., Moline M., Mackell J., Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dementia and Geriatric Cognitive Disorders 2012 33 2-3 164 173
31. Farlow M. R., Miller M. L., Pejovic V., Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dementia and Geriatric Cognitive Disorders 2008 25 5 408 422 2-s2.0-43049129669 10.1159/000122962 (Pubitemid 351630074)
32. Wallin A. K., Andreasen N., Eriksson S., Båtsman S., Näsman B., Ekdahl A., Kilander L., Grut M., Rydén M., Wallin A., Jonsson M., Olofsson H., Londos E., Wattmo C., Eriksdotter Jönhagen M., Minthon L., Björkman A., Wunsch A., Mannberg L., Källman A., Hellström I., Söderin M., Sjödin C., Grut M., Mohlin E., Dahl C., Gustavsson K., Holm B., Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dementia and Geriatric Cognitive Disorders 2007 23 3 150 160 2-s2.0-33847379394 10.1159/000098052 (Pubitemid 46333782)
33. Rountree S. D., Chan W., Pavlik V. N., Darby E. J., Siddiqui S., Doody R. S., Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimer's Research & Therapy 2009 1 2, article 7
34. Galasko D., Schmitt F., Thomas R., Jin S., Bennett D., Ferris S., Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. Journal of the International Neuropsychological Society 2005 11 4 446 453 2-s2.0-23844474755 10.1017/S1355617705050502 (Pubitemid 41167182)
35. Winblad B., Poritis N., Memantine in severe dementia: results of the MBest study (benefit and efficacy in severely demented patients during treatment with memantine). International Journal of Geriatric Psychiatry 1999 14 2 135 146 (Pubitemid 29110331)
36. Wilkinson D., Andersen H. F., Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2007 24 2 138 145 2-s2.0-34447633346 10.1159/000105162 (Pubitemid 47094073)
37. Wilkinson D., Schindler R., Schwam E., Waldemar G., Jones R. W., Gauthier S., Lopez O. L., Cummings J., Xu Y., Feldman H. H., Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2009 28 3 244 251 2-s2.0-70349432795 10.1159/000241877
38. Doody R. S., Tariot P. N., Pfeiffer E., Olin J. T., Graham S. M., Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimer's and Dementia 2007 3 1 7 17 2-s2.0-33846140141 10.1016/j.jalz.2006.10.004 (Pubitemid 46076022)
39. Schmitt F. A., van Dyck C. H., Wichems C. H., Olin J. T., Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Disease and Associated Disorders 2006 20 4 255 262 2-s2.0-33845452780 10.1097/01.wad.0000213860.35355. d4 (Pubitemid 44900939)
40. Lopez O. L., Becker J. T., Wahed A. S., Saxton J., Sweet R. A., Wolk D. A., Klunk W., DeKosky S. T., Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry 2009 80 6 600 607 2-s2.0-66149095869 10.1136/jnnp.2008.158964
41. Bond M., Rogers G., Peters J., The effectiveness and cost effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model. NIHR HTA Programme Project 2010 Number 09/87/01 London, UK National Institute for Clinical Excellence
42. Farrimond L. E., Roberts E., McShane R., Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open 2012 2 3 10.1136/bmjopen-2012-000917
43. Atri A., Shaughnessy L. W., Locascio J. J., Growdon J. H., Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Disease and Associated Disorders 2008 22 3 209 221 2-s2.0-52649127458 10.1097/WAD.0b013e31816653bc
44. Atri A., Rountree S. D., Lopez O. L., Doody R. S., Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegenerative Diseases 2012 10 1-4 170 174 2-s2.0-84860222723 10.1159/000335156
45. Zhu C. W., Sano M., Economic considerations in the management of Alzheimer's disease. Clinical interventions in aging 2006 1 2 143 154 2-s2.0-38449115010 10.2147/ciia.2006.1.2.143